MedTrace Logo

Multimodality- Adapted Dose Modification in Head and Neck Cancer Radiation Therapy 

NCT04933357 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2021-06-21

No results posted yet for this study

Summary

This is a prospective trial evaluating dose escalation using an SBRT boost to poor- responding tumors by interim functional imaging (PET/CT and fMRI) to improve the local control of HNCSCC.

Conditions

Interventions

RADIATION

Dose escalation

Dose escalation to poor responders to achieve dose equivalent more than 80 Gy using SBRT boost

RADIATION

Standard dose

Standard dose to good responders to achieve dose equivalent of 70 Gy.

Sponsors & Collaborators

  • National Cancer Institute, Egypt

    lead OTHER

Principal Investigators

  • Tarek Shouman · National Cancer Institute (NCI)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-16
Primary Completion
2022-09-30
Completion
2022-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04933357 on ClinicalTrials.gov